Artios Pharma Ltd. has recruited Simon Boulton as vice president for science strategy to help it develop new cancer treatments that target the DNA damage response, a network of cellular pathways responsible for detecting DNA damage and preventing disease. Dr Boulton will advise Artios in addition to carrying out his current job as a senior group leader at the Francis Crick Institute in London. He is also an honorary professor at University College London, an elected member of the European Molecular Biology Organization and a Fellow of the Academy of Medical Sciences.
Artios Pharma announced the appointment on 2 November 2016
Copyright 2016 Evernow Publishing Ltd